All In Biotech

Drug Trial Radar · NCT00209417

Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography

GEHC Has Decided Not to Provide This Detail But Will Rely on the Brief Title.

Last checked: Nov 19, 2026Latest source record: Oct 17, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 656 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

656

Actual

Start

Jun 2005

Primary completion

May 2011

Study completion Jul 2011

Sponsor

Lead sponsor
GE HealthcareIndustry
Sponsor type
Industry
Collaborators
ABX CRO; Examination Management Services Inc.; Covance; Quintiles, Inc.; Averion International Corporation
First posted
Sep 21, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

It is well known that X-ray contrast media can affect kidney function in some patients, especially when administered intra-arterially, and patients who already suffer from reduced kidney function and diabetes mellitus may be at increased risk. It is widely accepted to use low-osmolar or iso-osmolar contrast media, especially in patients at risk for contrast media-induced nephropathy. However, little is known about the intravenous use of X-ray contrast media in risk patients, such as contrast-enhanced CT examinations. The main purpose of this study is to evaluate and compare the effects on kidney function of two contrast media, the iso-osmolar iodixanol and the low-osmolar iopamidol in patients at risk of kidney damage associated with the injection of contrast media. Due to the iso-osmolar feature, it is expected less influence on renal function following administration of iodixanol. A standard hydration procedure, based on available guidelines will be given to all patients to prevent negative effects on the kidneys. Serum creatinine (SCr ) concentrations will be measured before and up to 7 days after contrast media administration to evaluate the effects on renal function.

Conditions

  • Renal Insufficiency
  • Diabetes Mellitus

Interventions

  • Iodixanol 320-Arm 1Drug

  • Iopamidol 300-Arm 2Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of the Incidence Rate of Contrast Medium-Induced Nephropathy (CIN) Between Iodixanol and Iopamidol in Patients With Impaired Renal Function.Time frame: From baseline up to 3 days post contrast administration.

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • GE Healthcare

    Princeton, New Jersey

  • GE Healthcare

    Amersham, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.